HC Wainwright declared research project in favor of medical activity and established a rigorous work plan in Investing.com’s MDNA11 study

HC Wainwright’s highest price is a market research and price of US$2.50 for Medicenna Therapeutics (NASDAQ: MDNA), a biotechnology laboratory in the clinical phase with a market capitalization of 110.87 million US dollars. The presentation follows the Clinical Presentation Date and the opening Phase-1/2-ABILITY-1-Study of the Unternehmen. The activity has dynamic dynamics and rapid growth in the transition period of an interest rate of 15.7% and a tax rate of 373.81% at the beginning of the month, as forecast by the InvestingPro date.

The study under MDNA11, an IL-2 agonist language for treating patients with strong writings to solidify tumors. The team will take place on December 5 at the Italian Association of Medical Oncology (AIOM) Immunotherapy Bridge 2024.

The drugs are recognized as the internal element of the monotherapy arms of the ABILITY-1 study according to the objective (ORR) 30% in patients with strong and/or metastasized tumors of Melanom, Nicht-Melanom-Hautkrebs or MSI-H/dMMR-Tumors berug. These patients received immune checkpoint inhibitor (ICI) therapy with a safety key and a use-for-use dose (RDE) of 90 µg/kg for two women.

This is a treatment for a melanoma patient in the best learning conditions (CR) that is, for a patient with MSI-H liver diseases, an in-depth study of the patient’s situation and non-metastasis metastases . wurde. This study is based on pembrolizumab, which is currently used for the treatment of MSI-H liver cancer (PDAC), in this patient group which has an ORR of 18.2%.

Darüber hinaus wurde bei sechs Patienten a stable Erkrankung (SD) festgestellt, was zu einer Krankheitskontrollrate (DCR) von 55% führte. Bei three dieser Patienten hielt die Stabilisierung länger als secchs Monate an. Agents that followed the use of CD25+, CD8+ and TCF-1+ immune programs under MDNA11 therapy were auf a potential for anhaltende hindeuten könnte experience.

According to Finanzieller Perspektive, the InvestingPro-Daten, the companies have a strong liquidity position with a number of short-term insurance obligations of the 11.4 aufweist and more bargeld and money in the balance sheet period. This play space is available for other specialized clinics.

MDNA11 has a dangerous safety profile, without reaching the toxicity dose limits (DLT). Most of the War of the Ereignisse Preparation (TRAE) took place between Levels 1 and 2 and took place within approximately 48 hours. Medicinal plant, in the first month of 2025, deadline for the presentation of the ABILITY-1 study as monotherapy.

Analyst consensus is expected to be positive, with prices ranging up to US$2.67 and US$3.56, resulting in high growth potential. For personalized financial age advice from Medicenna and potential analysts, you can contact investors with 10+ exclusive professional tips and comprehensive financial advice. InvestPro zugreifen.

This Übersetzung wurde mithilfe künstlicher Intelligenz erstellt. Please note that further information is required to provide additional information.